This article looks at the potential use of CBD oil as a primary treatment for lung cancer, based off a case study of an individual who declined conventional treatment for non-small cell lung cancer (NSCLC). The patient, a woman in her 80’s, was diagnosed with lung cancer in 2018 after observation of a 41mm lesion in the right middle lobe of her lung, and despite declining treatment, regular CT scans in 3-6 month intervals over a 2.5 year period showed the initial 41mm lesion had reduced to 10mm, representing an overall 76% reduction in axial diameter.
After being contacted the patient disclosed that she had been self-administering CBD oil 2-3 times daily off of advice from a family member since shortly after her diagnosis. The interactions of CBD with the endocannabinoid system can play roles such as regulating cell proliferation, differentiation, and apoptosis, which may potentially have played a role in the reduction in the size of the lesion. While this study by no means conclusively confirms that the tumour regression was due to the patient taking CBD oil, it does call for more research into the use of CBD in the field of oncology as a potential method of augmenting or replacing conventional primary treatments. This interest can then be compounded due to other research articles noting perceived properties of CBD that can be of benefit during traditional treatments, such as antiemetic, anti-inflammatory, and analgesic effects on the user.
Goodbody has no association with the organisation that conducted this research and is not in a position to validate the research methods, results or conclusions of the published article. It is provided for awareness of research available that may be of interest only. Any reader should read a range of articles and research to have a balanced and informed view.